Background: Pulmonary mucoepidermoid carcinoma (PMEC) and pulmonary adenoid cystic carcinoma (PACC) are the two major types of primary salivary gland-type (PSGT) lung cancers. The demographic profile, clinicopathological features, and predictors of survival as an overall group have not been described for PSGT cancers of lung.
Methods: In this study, we analyzed demographic, clinical, and survival data from 1,032 patients (546 PMEC and 486 PACC) who were diagnosed of PSGT lung cancer in the Surveillance, Epidemiology and End Results database from 1973 to 2014.
Results: The PSGT constituted 0.09% of all lung cancers with age-adjusted incidence rate of 0.07 per 100,000 person-years and change of -32% from 1973 to 2014. The incidence of PMEC was slightly higher than PACC but there were no differences in the age and sex distribution. PACCs (55%) were significantly higher at trachea and main bronchus while PMECs were more common at peripheral lungs (85%). Most of the tumors were diagnosed at an early stage and were low grade irrespective of histology. As compared to PMEC, significantly higher number of patients with PACC underwent radical surgery and received adjuvant radiation. The 1- and 5-year cause-specific survival was 76.6 and 62.8%, respectively. On multivariate analysis, the survival was affected by age at diagnosis, tumor stage, histological grade, period of diagnosis, and surgical resection. The histology showed strong interaction with time and hazard ratio of patients with PACC was significantly worse than patients with PMEC only after 5 years.
Conclusion: The incidence of pulmonary PSGT cancer is 7 cases per 10 million population in the United States and is decreasing. There was no difference between demographic profile of patients with PMEC and PACC but pathological features were diverse. The difference in the survival of patients with the two histological types surfaced only after 5 years when survival of patients with PMEC was better than PACC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5962707 | PMC |
| http://dx.doi.org/10.3389/fonc.2018.00153 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
From asthma exacerbation to pulmonary mucoepidermoid carcinoma: A rare case report.
Int J Surg Case Rep
December 2024
Department of Pathology, Al-Istishari Hospital, Ramallah, Palestine.
Introduction And Importance: Pulmonary mucoepidermoid carcinoma (PMEC) is a rare lung tumor, accounting 0.1-0.2 % of lung malignancies, commonly affecting adults under 50.
View Article and Find Full Text PDFThe Clinical Effect of a Propolis and Mangosteen Extract Complex in Subjects with Gingivitis: A Randomized, Double-Blind, and Placebo-Controlled Clinical Trial.
Nutrients
September 2024
Department of Periodontology, Institute of Oral Health Science, Ajou University School of Medicine, Suwon 16499, Republic of Korea.
This study investigated the efficacy and safety of a propolis-mangosteen extract complex (PMEC) on gingival health in patients with gingivitis and incipient periodontitis. A multicentered, randomized, double-blind, placebo-controlled trial involving 104 subjects receiving either PMEC or placebo for eight weeks was conducted. The primary focus was on the changes in inflammatory biomarkers from gingival crevicular fluid (GCF), with clinical parameters as secondary outcomes.
View Article and Find Full Text PDFLorlatinib in the treatment of a rare pulmonary mucoepidermoid carcinoma with EML4-ALK fusion: a case report and literature review.
Front Oncol
August 2024
Cancer Center, The First Hospital of Jilin University, Changchun, China.
Pulmonary mucoepidermoid carcinoma (PMEC) is a rare tumor with limited clinical data available due to its low incidence. So far, there are no universal treatment guidelines for this malignant tumor. We present here the case of a 59-year-old female never smoker who was initially referred to our hospital with cough and hemoptysis and was eventually diagnosed with PMEC.
View Article and Find Full Text PDFMucinous epidermoid carcinoma of the lung with ALK mutation: Case report and literature review.
Medicine (Baltimore)
May 2024
Department of Oncology, Handan First Hospital, Handan City, China.
Rationale: Pulmonary mucoepidermoid carcinoma (PMEC) is a rare lung malignancy, especially in combination with ALK mutations, whose clinical presentation lacks specificity and for which there are no standardized treatment guidelines.
Patient Concerns: We report a case of a patient with PMEC-predominant primary lung cancer combined with an ALK mutation.
Diagnoses: One patient was diagnosed with PMEC combined with ALK mutation.
Clinical presentation and treatment of four children with pulmonary mucoepidermoid carcinoma.
Ther Adv Respir Dis
June 2024
Department of Cardiothoracic Surgery, Chongqing Medical University Affiliated Children's Hospital, Chongqing 400000, China.
Primary lung cancer in childhood is extremely rare, with an incidence rate of less than 2/100,0000, and pulmonary mucoepidermoid carcinoma (PMEC), is even rarer. Their symptoms are usually not specific, and there are no guidelines for their management, which makes their clinical management a challenge for pediatricians. The purpose of this report is to discuss the clinical presentation, positive signs, examinations, pathological characteristics, surgical modalities, chemotherapy regimens, and prognosis in children.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!